source
- Company issues corporate announcement on senior employee transactionThe company released a corporate announcement identified as item 18/2026. The notice indicates that a transaction involving a leading employee has taken place. No further details about the nature…
- FDA grants accelerated approval to Replimune’s melanoma therapy Tudriqev after two prior rejectionsThe Food and Drug Administration has granted accelerated approval to Replimune’s RP1 treatment, which will be marketed under the name Tudriqev, for patients with advanced melanoma. An advisory com…